FDA Safety Labeling Changes for ACTEMRA (tocilizumab): What Changed, PV & Regulatory Impact, and a Playbook for Shudarsana
What changed in the U.S. label Newest update (August 8, 2025): Recent prior update (September 2024): Practical takeaway: Two concurrent risk domains now shape operations—expanded pediatric COVID-19 use (dosing, handling, benefit–risk) and heightened vigilance for severe hypersensitivity/SCARs. FDA Access Data+1 What needs to change internally (manufacturer/MAH “to-do” list) Pharmacovigilance impact Signal detection & case processing […]
Recent Safety Labeling Changes for BYOOVIZ
On August 15, 2025, the FDA approved safety-related labeling changes for BYOOVIZ (ranibizumab-nuna, BLA-761202) FDA Access Data. Key updates include: Impact on Pharmacovigilance Processes 1. Enhanced Signal Detection and Monitoring 2. Case Processing & Reporting 3. Update of Safety Documents 4. Risk Communication Impact on Regulatory Strategy 1. Labeling and Submission Updates 2. Compliance with […]